Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke; Edmond M. Kwan; Patricia Bukczynska; Nicole Ng; Tu Nguyen-Dumont; Melissa C. Southey; Ian D. Davis; Andrew Mant; Phillip Parente; Carmel Pezaro; Christine Hauser; Arun A. Azad

doi:10.1016/j.euf.2020.07.001

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A. Azad

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.

Original language	English
Number of pages	5
Journal	European Urology Focus
DOIs	https://doi.org/10.1016/j.euf.2020.07.001
Publication status	Accepted/In press - 1 Jan 2020

Keywords

Abiraterone
Androgen receptor pathway inhibitor
Biomarker
Castrate resistant
Cell-free DNA
Enzalutamide
Liquid biopsy
Prostate cancer

Access to Document

10.1016/j.euf.2020.07.001

Link to publication in Scopus

Cite this

Fettke, H., Kwan, E. M., Bukczynska, P., Ng, N., Nguyen-Dumont, T., Southey, M. C., Davis, I. D., Mant, A., Parente, P., Pezaro, C., Hauser, C., & Azad, A. A. (Accepted/In press). Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2020.07.001

Fettke, Heidi ; Kwan, Edmond M. ; Bukczynska, Patricia ; Ng, Nicole ; Nguyen-Dumont, Tu ; Southey, Melissa C. ; Davis, Ian D. ; Mant, Andrew ; Parente, Phillip ; Pezaro, Carmel ; Hauser, Christine ; Azad, Arun A. / Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer. In: European Urology Focus. 2020.

@article{d68516a7aaf547c9a2dcf72def52557d,

title = "Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer",

abstract = "A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.",

keywords = "Abiraterone, Androgen receptor pathway inhibitor, Biomarker, Castrate resistant, Cell-free DNA, Enzalutamide, Liquid biopsy, Prostate cancer",

author = "Heidi Fettke and Kwan, {Edmond M.} and Patricia Bukczynska and Nicole Ng and Tu Nguyen-Dumont and Southey, {Melissa C.} and Davis, {Ian D.} and Andrew Mant and Phillip Parente and Carmel Pezaro and Christine Hauser and Azad, {Arun A.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/j.euf.2020.07.001",

language = "English",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

}

Fettke, H, Kwan, EM, Bukczynska, P, Ng, N, Nguyen-Dumont, T , Southey, MC , Davis, ID, Mant, A, Parente, P, Pezaro, C, Hauser, C & Azad, AA 2020, 'Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer', European Urology Focus. https://doi.org/10.1016/j.euf.2020.07.001

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer. / Fettke, Heidi; Kwan, Edmond M.; Bukczynska, Patricia; Ng, Nicole; Nguyen-Dumont, Tu ; Southey, Melissa C.; Davis, Ian D.; Mant, Andrew; Parente, Phillip; Pezaro, Carmel; Hauser, Christine; Azad, Arun A.

In: European Urology Focus, 01.01.2020.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

AU - Fettke, Heidi

AU - Kwan, Edmond M.

AU - Bukczynska, Patricia

AU - Ng, Nicole

AU - Nguyen-Dumont, Tu

AU - Southey, Melissa C.

AU - Davis, Ian D.

AU - Mant, Andrew

AU - Parente, Phillip

AU - Pezaro, Carmel

AU - Hauser, Christine

AU - Azad, Arun A.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.

AB - A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.

KW - Abiraterone

KW - Androgen receptor pathway inhibitor

KW - Biomarker

KW - Castrate resistant

KW - Cell-free DNA

KW - Enzalutamide

KW - Liquid biopsy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85089008818&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2020.07.001

DO - 10.1016/j.euf.2020.07.001

M3 - Article

C2 - 32739405

AN - SCOPUS:85089008818

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -